公开(公告)号：US20250092042A1

公开(公告)日：2025-03-20

申请号：US18924066

申请日：2024-10-23

Applicant: NOVARTIS AG

Inventor： Mallesh BUSHABOINA ,  Xin CHEN ,  Atwood Kim CHEUNG ,  Andrew James CULSHAW ,  Timothy Brian HURLEY ,  Nancy LABBE-GIGUERE ,  Wolfgang MILTZ ,  David ORAIN ,  Tajesh PATEL ,  Srinivasan RAJAGOPALAN ,  Till ROEHN ,  David Andrew SANDHAM ,  Gebhard THOMA ,  Ritesh Bhanudasji TICHKULE ,  Rudolf WÄLCHLI

IPC: C07D471/10 ,  A61K45/06 ,  C07D519/00

Abstract: The present invention provides a method for manufacturing a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein.

公开(公告)号：US20240140959A1

公开(公告)日：2024-05-02

申请号：US18497296

申请日：2023-10-30

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James Anthony NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D491/107 ,  A61K45/06 ,  A61P25/18

CPC classification number: C07D491/107 ,  A61K45/06 ,  A61P25/18

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20210107889A1

公开(公告)日：2021-04-15

申请号：US17065360

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D401/04

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20240043425A1

公开(公告)日：2024-02-08

申请号：US18319585

申请日：2023-05-18

Applicant: NOVARTIS AG

Inventor： Mallesh BUSHABOINA ,  Xin CHEN ,  Atwood Kim CHEUNG ,  Andrew James CULSHAW ,  Timothy Brian HURLEY ,  Nancy LABBE-GIGUERE ,  Wolfgang MILTZ ,  David ORAIN ,  Tajesh PATEL ,  Srinivasan RAJAGOPALAN ,  Till ROEHN ,  David Andrew SANDHAM ,  Gebhard THOMA ,  Ritesh Bhanudasji TICHKULE ,  Rudolf WÄLCHLI

IPC: C07D471/10 ,  A61K45/06 ,  C07D519/00

CPC classification number: C07D471/10 ,  C07D519/00 ,  A61K45/06

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;






wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20230212139A1

公开(公告)日：2023-07-06

申请号：US18062356

申请日：2022-12-06

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D401/04

CPC classification number: C07D401/04 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I)




or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20250115572A1

公开(公告)日：2025-04-10

申请号：US18729949

申请日：2023-01-20

Applicant: Novartis AG

Inventor： Christopher M. ADAMS ,  Lara C. CZABANIUK ,  Stefanie FLOHR ,  François GESSIER ,  Michael Christoph HEDIGER ,  Konstanze HURTH ,  Nancy LABBE-GIGUERE ,  Fabio LIMA ,  Tajesh PATEL ,  Oliver SIMIC ,  Martin SENDZIK ,  Angela VITREY ,  Anna VULPETTI

IPC: C07D401/06 ,  A61K31/438 ,  A61K31/444 ,  C07D401/14 ,  C07D405/14

Abstract: Provided herein are compounds of formula (I) and pharmaceutical compositions thereof useful for treating diseases or disorders mediated by the complement factor B. (I).

公开(公告)号：US20220411435A1

公开(公告)日：2022-12-29

申请号：US17818321

申请日：2022-08-08

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D491/107 ,  A61P25/18 ,  A61K45/06

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

公开(公告)号：US20210130365A1

公开(公告)日：2021-05-06

申请号：US17065367

申请日：2020-10-07

Applicant: NOVARTIS AG

Inventor： Amy CALHOUN ,  Xin CHEN ,  Kevin Matthew GARDINIER ,  Edward Charles HALL ,  Keith JENDZA ,  Nancy LABBE-GIGUERE ,  James NEEF ,  Daniel Steven PALACIOS ,  Ming QIAN ,  Michael David SHULTZ ,  Christopher G. THOMSON ,  Kate Yaping WANG ,  Fan YANG

IPC: C07D491/107 ,  A61K45/06 ,  A61P25/18

Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.